NS002

Sept. 14, 2026: Nasus Pharma Ltd. (NYSE: NSRX) said the FDA cleared its IND for NS002, an investigational intranasal epinephrine powder for treatment of anaphylaxis/Type I allergic reactions. The cleared clinical study will evaluate NS002 as a needle-free alternative to EpiPen and compare patient self-administration with administration by a healthcare professional.

The company said it plans to start a pivotal study in Q4 2026, with topline data expected in Q1 2027.

Nasus also cited prior Phase 2 results for NS002: the product reached the 100 pg/mL plasma epinephrine threshold with a median T100 of 1.69 minutes versus 3.47 minutes for EpiPen. Current status is regulatory clearance to proceed into the next clinical stage, with pivotal data as the next named catalyst.